Middle East & Africa Blood-based Biomarker For Alzheimer’s Disease Diagnostics Market (2025 - 2033) Size, Share & Trends Analysis Report By Type (Amyloid-related Markers, Tau-related Markers), By Technology, By End-use, By Country, And Segment Forecasts

Market Size & Trends

The Middle East & Africa blood-based biomarker for Alzheimer’s disease diagnostics market size was estimated at USD 6.22 million in 2024 and is expected to reach USD 13.11 million by 2033, growing at a CAGR of 9.77% from 2025 to 2033. Rising awareness of neurodegenerative diseases, coupled with an aging population across the region, is fueling demand for early detection tools. Traditionally, Alzheimer’s diagnosis has relied on expensive and invasive methods such as PET imaging or cerebrospinal fluid (CSF) testing, which are often limited in availability across MEA. Blood-based biomarkers offer a cost-effective, scalable, and minimally invasive alternative, making them particularly attractive in regions with constrained healthcare infrastructure.

As governments prioritize healthcare modernization and invest in early detection programs, adoption of blood biomarker tests is expected to expand. Market growth is also supported by international collaborations, local clinical trials, and the entry of global biotech companies into MEA, further bridging the gap between advanced Western technologies and regional healthcare needs.

Population aging and the regional dementia burden are powerful demand drivers. The Arab world had ~1.33 million people with dementia in 2021, while the WHO estimates 57 million globally (60-70% Alzheimer’s), with most cases in low/middle-income countries-categories that include many MEA markets. In Africa, studies report dementia incidence ~13.3 per 1,000 person-years and wide prevalence ranges (2.3–20%), underscoring unmet diagnostic need. Five reasons this pushes BBMs: (1) growing at-risk 65+ cohorts; (2) earlier detection improves care planning; (3) primary-care-friendly testing expands reach; (4) caregiver and societal burden pressures ministries to act; and (5) health-system KPI shifts toward chronic-disease management. Country snapshots illustrate heterogeneity: Lebanon shows high point prevalence (~828/100k), while the UAE is lower (~652/100k)-but rapid population aging and high health spending can still sustain demand. Together, these epidemiological realities create a durable, multi-year addressable market for AD BBMs.

Capital flows into MEA healthcare expand diagnostic capacity and BBM adoption. Saudi Arabia’s Vision 2030 Health Sector Transformation Program is overhauling delivery models, while 2024 budget updates cite USD 57 billion for health/social development-funds that often translate into new labs, LIMS, and quality programs.

Clinical validation and workflow impact underpin adoption. NIH-reported studies show blood tests identifying AD with ~90% accuracy, while real-world evaluations of PrecivityAD2 demonstrate that BBMs change clinician-reported AD probability and alter downstream care (e.g., medication plans, additional amyloid testing)

Market Concentration & Characteristics

The MEA market is witnessing rapid innovation through next-generation biomarkers targeting amyloid and phosphorylated tau, improving diagnostic accuracy over traditional methods. Integration of AI and digital health platforms enhances predictive modeling and patient stratification. Novel lab-on-chip technologies and automated immunoassay analyzers are making blood-based biomarker (BBM) testing more scalable, enabling earlier Alzheimer’s disease detection, better accessibility, and reducing reliance on costly PET imaging and invasive CSF testing.

Mergers and acquisitions are shaping the competitive landscape as global diagnostics firms seek entry into emerging MEA markets. Strategic alliances between biotech companies, diagnostic developers, and regional healthcare providers help accelerate product distribution and technology transfer. Partnerships such as Biogen–Beckman Coulter–Fujirebio highlight the industry’s focus on advancing tau biomarker research, while local distributors and labs increasingly align with multinational players to expand test accessibility across Gulf and African countries.

Regulatory bodies in MEA are increasingly influenced by international benchmarks, such as the FDA’s 2025 approval of the first Alzheimer’s blood test. These precedents accelerate regional approvals, boosting adoption. Gulf nations, notably Saudi Arabia and the UAE, are leading regulatory modernization under Vision 2030 initiatives, prioritizing innovative diagnostics. Clearer approval pathways, reimbursement frameworks, and clinical guidelines are expected to encourage broader acceptance of BBMs in public and private healthcare systems.

Product portfolios in the MEA market are expanding beyond amyloid-focused assays to include tau, neurofilament light chain (NfL), and multi-marker panels, enhancing diagnostic reliability. Companies are localizing assay production and offering automated analyzers to adapt to regional laboratory capacities. Expansion into treatment-linked companion diagnostics is also emerging, as blood tests increasingly guide eligibility for disease-modifying Alzheimer’s therapies, creating new growth opportunities and strengthening the value proposition of BBM technologies in MEA.

Regional expansion is driven by rising healthcare investments and growing dementia prevalence in MEA. The UAE recently introduced its first early Alzheimer’s detection center using blood testing, setting a precedent for broader adoption. Saudi Arabia, South Africa, and Egypt are emerging as key growth markets, supported by government-led healthcare reforms. Global firms are collaborating with local distributors and research institutions, improving access and embedding BBMs into evolving dementia care infrastructures.

Type  Insights

On the basis of type, Tau-related markers accounted for the largest market share of 37.01% in 2024, driven by strong clinical evidence linking phosphorylated tau (p-tau) proteins-particularly p-tau181, p-tau217, and p-tau231-to early. Tau pathology, particularly phosphorylated tau (p-tau) species such as p-tau181 and p-tau217, is gaining recognition as a highly specific marker of neurodegeneration and disease progression. Gulf states like Saudi Arabia and the UAE are investing heavily in innovative diagnostics under national health reforms, positioning them as early adopters of tau-based assays. As pharmaceutical companies advance anti-tau therapies, demand for companion diagnostics in MEA is set to grow, strengthening tau-related markers as a key market segment.

The amyloid-related markers segment is anticipated to grow steadily, as amyloid beta (Aβ) pathology remains a hallmark feature of the disease. Countries such as the UAE and Saudi Arabia are spearheading early implementation through innovation hubs and memory clinics, integrating amyloid testing into dementia care pathways. In Africa, where PET imaging and lumbar punctures are less accessible, blood-based amyloid assays present a cost-effective and scalable diagnostic alternative. With dementia prevalence expected to rise sharply-Africa alone is projected to see cases triple by 2050-amyloid-based tests are positioned as the gateway diagnostic tool. Their widespread clinical acceptance, cost advantages, and role in guiding anti-amyloid therapy access ensure continued market growth in MEA.

Technology Insights

Immunoassays held the largest market share in 2024, driven by their scalability, cost-effectiveness, and established role in clinical laboratories. Enzyme-linked immunosorbent assays (ELISA) and automated chemiluminescence immunoassays are widely used to measure amyloid-beta, tau, and neurofilament light chain proteins, offering a practical alternative to PET imaging and CSF analysis. In MEA, adoption is fueled by rising healthcare investments, particularly in Gulf states like Saudi Arabia and the UAE, where laboratory automation and precision medicine initiatives are being prioritized under national health strategies. Immunoassays are also attractive in Africa due to their compatibility with existing laboratory infrastructure, making them more feasible than advanced molecular platforms in resource-limited settings.

The next-generation platforms segment is expected to grow at the fastest rate over the forecast period. These technologies offer enhanced sensitivity for detecting low-abundance biomarkers like phosphorylated tau and amyloid-beta isoforms, enabling earlier and more precise diagnosis. In MEA, Gulf countries such as the UAE and Saudi Arabia are spearheading adoption, supported by investments in precision medicine, AI-enabled health analytics, and smart lab infrastructure under national transformation agendas. For Africa, while adoption may be slower due to cost and technical complexity, public–private partnerships and donor-supported innovation hubs are expected to accelerate access over the next decade. Importantly, next-generation platforms align with the region’s push toward personalized medicine and clinical trial participation, particularly as anti-amyloid and anti-tau therapies advance.

End-use Insights

Clinical laboratories & hospital labs dominated the market in 2024, reflecting their central role in diagnostic services and patient care. These facilities serve as the primary hubs for test deployment, supported by their established infrastructure, advanced equipment, and integration into clinical workflows. Hospitals are also key players in clinical validation, partnering with global diagnostic companies to pilot amyloid and tau-based assays within routine care. In Africa, where diagnostic infrastructure is limited, urban hospitals are expected to lead adoption, serving as regional referral centers for BBM-based Alzheimer’s screening. As disease-modifying therapies enter the market, hospitals will remain central to linking diagnostics with treatment pathways.

The others segment in the Middle East and Africa is expected to grow at the fastest rate over the forecast period. Memory clinics and senior care centers are increasingly adopting blood-based biomarker tests to enable community-level early detection, addressing the rising burden of dementia in aging populations. CROs are leveraging these assays for clinical trial recruitment and monitoring, particularly for emerging anti-amyloid and neuroprotective therapies that require biomarker confirmation for enrollment. Diagnostic centers are also integrating blood-based tests as non-invasive, cost-effective adjuncts to imaging methods like PET scans.

Country Insight

South Africa Blood-based Biomarker for Alzheimer’s Disease Diagnostics Market Trends

South Africa’s market growth is driven by a rising dementia burden-scases are expected to nearly triple across Africa by 2050 and a growing demand for accessible, cost-effective diagnostics. Limited availability of PET scanners and specialist neurologists makes blood-based biomarkers an attractive alternative. Urban hospitals in Johannesburg and Cape Town are emerging as hubs for advanced diagnostics, partnering with global firms to pilot BBM solutions. Government investment in non-communicable disease management and increasing private healthcare expenditure are also fostering adoption. As BBMs expand beyond amyloid into tau detection, South Africa’s healthcare ecosystem is positioned to integrate these innovations for earlier Alzheimer’s detection, reducing reliance on invasive CSF tests.

Saudi Arabia Blood-based Biomarker for Alzheimer’s Disease Diagnostics Market Trends

The Saudi Arabian market is supported by Vision 2030 reforms emphasizing innovation and precision medicine. With an ageing population over 10% projected to be 60+ by 2030, the demand for scalable Alzheimer’s testing is rising. Hospitals in Riyadh and Jeddah are investing in advanced lab automation and neurology services, creating an enabling environment for amyloid and tau biomarker adoption. Government-led healthcare digitization and AI integration further strengthen BBM utility by linking test results with electronic health records for early intervention.

UAE Blood-based Biomarker for Alzheimer’s Disease Diagnostics Market Trends

The UAE market is expanding rapidly due to strong healthcare innovation policies and early adoption of novel diagnostics. Abu Dhabi’s establishment of the first regional center offering Alzheimer’s blood tests highlights its role as a pioneer. With dementia prevalence projected to rise alongside increased life expectancy, blood based biomarkers provide a non-invasive, cost-effective solution for early detection and monitoring. The UAE’s significant investments in digital health, AI-driven analytics, and smart laboratories enhance the diagnostic ecosystem, making next-generation platforms and companion diagnostics more feasible. Furthermore, the country’s robust private healthcare sector, medical tourism initiatives, and partnerships with global biotech firms support technology transfer and product availability.

Key MEA Blood-based Biomarker For Alzheimer’s Disease Diagnostics Companies Insights

Key players operating in the MEA blood-based biomarker for Alzheimer’s disease diagnostics market are undertaking various initiatives to strengthen their presence and increase the reach of their products and services. Strategies such as expansion activities and partnerships are key in propelling the market growth.

Recent Developments

• In July 2025, C2N Diagnostics, LLC, a leader in advanced brain health diagnostics, introduced two new plasma assays for Research Use Only: C2N eMTBR-tau243 and C2N %p-tau MAA. The C2N eMTBR-tau243 test targets a distinct microtubule binding region of tau in the blood. This fragment has been shown to closely mirror insoluble tau aggregates found in neurofibrillary tangles, a key hallmark of Alzheimer’s disease.

• In July 2024, Biogen Inc., Beckman Coulter, Inc., and Fujirebio announced a collaboration aimed at identifying and developing blood-based biomarkers for tau pathology in the brain, with the potential to clinically advance and commercialize new diagnostic tests for Alzheimer’s disease (AD). These tau-specific blood biomarkers, designed to measure a patient’s tau burden, could offer valuable insights into the disease’s underlying mechanisms and support the development of next-generation therapies targeting tau pathology.

• In July 2023, Quanterix Corporation, a provider of ultrasensitive biomarker detection driving scientific discovery and diagnostic innovation, announced the launch of LucentAD-a test designed to support the evaluation of patients showing cognitive symptoms associated with early Alzheimer’s disease (AD). Intended for use alongside other diagnostic methods, LucentAD offers healthcare providers a streamlined way to assess the probability that a patient has amyloid pathology consistent with AD.

MEA Blood-based Biomarker For Alzheimer’s Disease Diagnostics Market Report Scope

MEA Blood-based Biomarker For Alzheimer’s Disease Diagnostics Market Report Segmentation

This report forecasts revenue growth at the regional and country levels and provides an analysis of the latest trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the Middle East & Africa blood-based biomarker for Alzheimer’s disease diagnostics market report based on type, technology, end-use, and country:

• Type Outlook (Revenue, USD Million, 2021 - 2033)

  • Amyloid-related markers

  • Tau-related markers

  • Neurodegeneration

  • Others

• Technology Outlook (Revenue, USD Million, 2021 - 2033)

  • Immunoassays

  • Mass spectrometry-based assays

  • Next-generation platforms

  • Others

• End-use Outlook (Revenue, USD Million, 2021 - 2033)

  • Clinical laboratories & hospital labs

  • Pharma & biotech

  • Academic & research institutes

  • Others

• Country Outlook (Revenue, USD Million, 2021 - 2033)

  • South Africa

  • Saudi Arabia

  • UAE

  • Kuwait